cemiplimab
sanofi,regeneron
['cemiplimab']
eye popping results for neo-adjuvant anti-pd1 in cutaneous scc --- ~ 50% pathcr; further 13% with major path response (&gt;90% response) to 4 cycles of cemiplimab (anti-pd1). wow! @ #esmo22 &amp; in by and team. 
Head and Neck Oncologist (radiation) & Computational Biologist. Interests in cancer genomics, immunotherapy & DNA repair. @sloan_kettering